The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
A Versatile Platform to Analyze Low-Affinity and Transient Protein-Protein Interactions in Living Cells in Real Time
Abstract
Protein-protein interactions (PPIs) play central roles in orchestrating biological processes. While some PPIs are stable, many important ones are transient and hard to detect with conventional approaches. We developed ReBiL, a recombinase enhanced bimolecular luciferase complementation platform, to enable detection of weak PPIs in living cells. ReBiL readily identified challenging transient interactions between an E3 ubiquitin ligase and an E2 ubiquitin-conjugating enzyme. ReBiL's ability to rapidly interrogate PPIs in diverse conditions revealed that some stapled α-helical peptides, a class of PPI antagonists, induce target-independent cytosolic leakage and cytotoxicity that is antagonized by serum. These results explain the requirement for serum-free conditions to detect stapled peptide activity, and define a required parameter to evaluate for peptide antagonist approaches. ReBiL's ability to expedite PPI analysis, assess target specificity and cell permeability, and reveal off-target effects of PPI modifiers should facilitate the development of effective, cell-permeable PPI therapeutics and the elaboration of diverse biological mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A previous study suggested that SAH-p53-8-induced cell death is correlated with cytoplasmic leakage through disruption of the cell membrane.374”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [374]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Wadia, J. S., Stan, R. V., & Dowdy, S. F. (2004) · Nature Medicine · doi:10.1038/nm996 · Cited by 1,647
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Self-citationAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 4×
“Therefore, availability of drugs that interfere with p53-Mdm2 and p53-Mdm4 interactions could restore p53 function and significantly benefit patients whose cancers express wild type p53 (Brown et al., 2009; Wade et al., 2013).”
BackgroundMethodInfluentialTranscriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569
Targeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391 · cited 1×
“We also examined the activities of several PMI-based p53-Mdm2 and p53-Mdm4 antagonists, as these are high affinity Mdm2-binding peptides obtained through screening phage display libraries (Pazgier et al., 2009) (Table S3 and Supplemental Experimental Procedures).”
Method
Research works printed but not linked: 35
- Bernal, 2007, Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide, J. Am. Chem. Soc., 129, 2456, 10.1021/ja0693587 · DOI · Paper page
- Bernal, 2010, A stapled p53 helix overcomes HDMX-mediated suppression of p53, Cancer Cell, 18, 411, 10.1016/j.ccr.2010.10.024 · DOI · Paper page
- Bird, 2014, Distinct BimBH3 (BimSAHB) stapled peptides for structural and cellular studies, ACS Chem. Biol., 9, 831, 10.1021/cb4003305 · DOI
- Brown, 2013, Stapled peptides with improved potency and specificity that activate p53, ACS Chem. Biol., 8, 506, 10.1021/cb3005148 · DOI · Paper page
- Brzovic, 2001, Structure of a BRCA1-BARD1 heterodimeric RING-RING complex, Nat. Struct. Biol., 8, 833, 10.1038/nsb1001-833 · DOI
- Cassonnet, 2011, Benchmarking a luciferase complementation assay for detecting protein complexes, Nat. Methods, 8, 990, 10.1038/nmeth.1773 · DOI · Paper page
- Chang, 2013, Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy, Proc. Natl. Acad. Sci. USA, 110, E3445, 10.1073/pnas.1303002110 · DOI · Paper page
- Edwards, 2013, Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3, Chem. Biol., 20, 888, 10.1016/j.chembiol.2013.06.007 · DOI
- Gilad, 2014, Discovering protein-protein interactions within the programmed cell death network using a protein-fragment complementation screen, Cell Rep, 8, 909, 10.1016/j.celrep.2014.06.049 · DOI
- Green, 2013, Use of a molecular genetic platform technology to produce human Wnt proteins reveals distinct local and distal signaling abilities, PLoS ONE, 8, e58395, 10.1371/journal.pone.0058395 · DOI
- Herce, 2013, Visualization and targeted disruption of protein interactions in living cells, Nat Commun, 4, 2660, 10.1038/ncomms3660 · DOI · Paper page
- Hodson, 2011, Structural analysis of human FANCL, the E3 ligase in the Fanconi anemia pathway, J. Biol. Chem., 286, 32628, 10.1074/jbc.M111.244632 · DOI
- Hodson, 2014, Structure of the human FANCL RING-Ube2T complex reveals determinants of cognate E3-E2 selection, Structure, 22, 337, 10.1016/j.str.2013.12.004 · DOI
- Ilagan, 2011, Real-time imaging of notch activation with a luciferase complementation-based reporter, Sci. Signal., 4, rs7, 10.1126/scisignal.2001656 · DOI
- Joerger, 2008, Structural biology of the tumor suppressor p53, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
- Lee, 2011, Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactions, J. Am. Chem. Soc., 133, 676, 10.1021/ja108230s · DOI
- Levy, 2014, High-resolution mapping of protein concentration reveals principles of proteome architecture and adaptation, Cell Rep, 7, 1333, 10.1016/j.celrep.2014.04.009 · DOI
- Liu, 2010, D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms, Proc. Natl. Acad. Sci. USA, 107, 14321, 10.1073/pnas.1008930107 · DOI · Paper page
- Luker, 2004, Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals, Proc. Natl. Acad. Sci. USA, 101, 12288, 10.1073/pnas.0404041101 · DOI · Paper page
- Macdonald-Obermann, 2012, Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging, Proc. Natl. Acad. Sci. USA, 109, 137, 10.1073/pnas.1111316109 · DOI
- Machida, 2006, UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation, Mol. Cell, 23, 589, 10.1016/j.molcel.2006.06.024 · DOI · Paper page
- Magzoub, 2005, Membrane perturbation effects of peptides derived from the N-termini of unprocessed prion proteins, Biochim. Biophys. Acta, 1716, 126, 10.1016/j.bbamem.2005.09.009 · DOI
- Michnick, 2007, Universal strategies in research and drug discovery based on protein-fragment complementation assays, Nat. Rev. Drug Discov., 6, 569, 10.1038/nrd2311 · DOI · Paper page
- Moldovan, 2009, How the fanconi anemia pathway guards the genome, Annu. Rev. Genet., 43, 223, 10.1146/annurev-genet-102108-134222 · DOI · Paper page
- Okamoto, 2014, Further insights into the effects of pre-organizing the BimBH3 helix, ACS Chem. Biol., 9, 838, 10.1021/cb400638p · DOI
- Paulmurugan, 2007, Combinatorial library screening for developing an improved split-firefly luciferase fragment-assisted complementation system for studying protein-protein interactions, Anal. Chem., 79, 2346, 10.1021/ac062053q · DOI
- Rossi, 2000, Transcriptional control: rheostat converted to on/off switch, Mol. Cell, 6, 723, 10.1016/S1097-2765(00)00070-8 · DOI
- Stumpf, 2008, Estimating the size of the human interactome, Proc. Natl. Acad. Sci. USA, 105, 6959, 10.1073/pnas.0708078105 · DOI · Paper page
- Venkatesan, 2009, An empirical framework for binary interactome mapping, Nat. Methods, 6, 83, 10.1038/nmeth.1280 · DOI · Paper page
- Verdine, 2012, Stapled peptides for intracellular drug targets, Methods Enzymol., 503, 3, 10.1016/B978-0-12-396962-0.00001-X · DOI · Paper page
- Wade, 2008, BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death, Cell Cycle, 7, 1973, 10.4161/cc.7.13.6072 · DOI · Paper page
- Wells, 2007, Reaching for high-hanging fruit in drug discovery at protein-protein interfaces, Nature, 450, 1001, 10.1038/nature06526 · DOI · Paper page
- Wong, 2005, Reproducible doxycycline-inducible transgene expression at specific loci generated by Cre-recombinase mediated cassette exchange, Nucleic Acids Res., 33, e147, 10.1093/nar/gni145 · DOI
- Yang, 2009, Luciferase fragment complementation imaging of conformational changes in the epidermal growth factor receptor, J. Biol. Chem., 284, 7474, 10.1074/jbc.M808041200 · DOI
- Ye, 2009, Building ubiquitin chains: E2 enzymes at work, Nat. Rev. Mol. Cell Biol., 10, 755, 10.1038/nrm2780 · DOI · Paper page
Cited by
Understanding Cell Penetration of Cyclic Peptides
Dougherty, P. G., Sahni, A., & Pei, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00008 · Cited by 570
Hydrocarbon Stapled Peptides as Modulators of Biological Function
Cromm, P. M., Spiegel, J., & Grossmann, T. N. (2015) · ACS Chemical Biology · doi:10.1021/cb501020r · Cited by 290
Discovery and characterization of smORF-encoded bioactive polypeptides
Saghatelian, A., & Couso, J. P. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1964 · Cited by 286
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Li, Y.-C., Rodewald, L. W., Hoppmann, C., Wong, E. T., Lebreton, S., Safar, P., Patek, M., Wang, L., Wertman, K. F., & Wahl, G. M.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 9
- Issue
- 5
- Pages
- 1946-1958
- ISSN
- 2211-1247
- Cited by
- 79
- References
- 16
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.